
Sharon Paton

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/972089/publications.pdf Version: 2024-02-01



#	Article	IF	CITATION
1	Ageing human bone marrow mesenchymal stem cells have depleted NAD(P)H and distinct multispectral autofluorescence. GeroScience, 2021, 43, 859-868.	2.1	11
2	Distinct Senescent Bone Marrow Microenvironment in Therapy-Related Myeloid Neoplasms. Blood, 2021, 138, 2585-2585.	0.6	1
3	Conditional knockout of ephrinB1 in osteogenic progenitors delays the process of endochondral ossification during fracture repair. Bone, 2020, 132, 115189.	1.4	8
4	Therapy-Related Myeloid Neoplasm Has a Distinct Pro-Inflammatory Bone Marrow Microenvironment and Delayed DNA Damage Repair. Blood, 2020, 136, 37-38.	0.6	0
5	Non-destructive, label free identification of cell cycle phase in cancer cells by multispectral microscopy of autofluorescence. BMC Cancer, 2019, 19, 1242.	1.1	22
6	Loss of EfnB1 in the osteogenic lineage compromises their capacity to support hematopoietic stem/progenitor cell maintenance. Experimental Hematology, 2019, 69, 43-53.	0.2	14
7	The osteoprogenitor-specific loss of ephrinB1 results in an osteoporotic phenotype affecting the balance between bone formation and resorption. Scientific Reports, 2018, 8, 12756.	1.6	15
8	Pentosan polysulfate binds to STRO-1+ mesenchymal progenitor cells, is internalized, and modifies gene expression: a novel approach of pre-programing stem cells for therapeutic application requiring their chondrogenesis. Stem Cell Research and Therapy, 2017, 8, 278.	2.4	8
9	Loss of ephrinB1 in osteogenic progenitor cells impedes endochondral ossification and compromises bone strength integrity during skeletal development. Bone, 2016, 93, 12-21.	1.4	19
10	EphB4 Expressing Stromal Cells Exhibit an Enhanced Capacity for Hematopoietic Stem Cell Maintenance. Stem Cells, 2015, 33, 2838-2849.	1.4	29
11	Incremental benefits of repeated mesenchymal stromal cell administration compared with solitary intervention after myocardial infarction. Cytotherapy, 2014, 16, 460-470.	0.3	20
12	Impact of Timing and Dose of Mesenchymal Stromal Cell Therapy in a Preclinical Model of Acute Myocardial Infarction. Journal of Cardiac Failure, 2013, 19, 342-353.	0.7	43
13	Comparative Assessment of the Osteoconductive Properties of Different BiomaterialsIn VivoSeeded with Human or Ovine Mesenchymal Stem/Stromal Cells. Tissue Engineering - Part A, 2010, 16, 3579-3587.	1.6	33
14	Heat Shock Protein-90 beta Is Expressed at the Surface of Multipotential Mesenchymal Precursor Cells: Generation of a Novel Monoclonal Antibody, STRO-4, With Specificity for Mesenchymal Precursor Cells From Human and Ovine Tissues. Stem Cells and Development, 2009, 18, 1253-1262.	1.1	70
15	Human mulipotential mesenchymal/stromal stem cells are derived from a discrete subpopulation of STRO-1bright/CD34 /CD45 /glycophorin-A-bone marrow cells. Haematologica, 2007, 92, 1707-1708.	1.7	72